Clinically, in breast cancer protein expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2) direct breast cancer treatments and are routinely assessed by immunohistochemical (IHC) staining. This evidence concerns the gene ERBB2 and breast carcinoma.